AG
DNA icon

AmeriFlex Group’s Ginkgo Bioworks DNA Stock Holding History

AmeriFlex Group’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-92
Closed -$884 – 1134
2025
Q2 		$884 Hold
92
– – ﹤0.01% 1007
2025
Q1 		$524 Hold
92
– – ﹤0.01% 1234
2024
Q4 		$1.23K Buy
+92
New +$788 ﹤0.01% 1090

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AmeriFlex Group's DNA Position: Q3 2025 in Review

AmeriFlex Group sold out of Ginkgo Bioworks (DNA) in Q3 2025, closing a stake of 92 shares — an estimated $884 sold.

AmeriFlex Group first reported a position in DNA in Q4 2024 and held it in 3 quarters. The position peaked at $1.23K in Q4 2024. 174 funds tracked by Wall St. Rank hold DNA as of Q3 2025.

  • AmeriFlex Group reported no remaining Ginkgo Bioworks position as of Q3 2025 after selling out during the quarter.
  • AmeriFlex Group sold 92 Ginkgo Bioworks shares in Q3 2025, an estimated $884.
  • AmeriFlex Group first reported a position in Ginkgo Bioworks in Q4 2024 and held it in 3 quarters.
  • AmeriFlex Group's Ginkgo Bioworks position peaked at $1.23K in Q4 2024.
  • 174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2025.

Based on AmeriFlex Group's 13F filing for Q3 2025, filed 12 Nov 2025.